Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05135286 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
A Phase 3 study of Presbyopia, sponsored by Visus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 629
- Enrollment target
- 20
- Study locations
NCT05135286: Completed Phase 3 study of Presbyopia, sponsored by Visus Therapeutics.
NCT05135286 is a Phase 3 study of Presbyopia that has completed, run by Visus Therapeutics. The registered enrollment target is 629 participants, above the 254-participant average among 38 other Presbyopia trials with a reported enrollment target (148% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05135286, a Phase 3 study of Presbyopia, has completed, sponsored by Visus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 629 participants
- Enrollment target
- 20
- Study locations
Study Summary
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Primary Outcome
Percentage of subjects with 3-line improvement in near VA without the loss of at least 1 line in distance VA
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG BRIMOCHOL™ PF
- DRUG Carbachol PF
Study Locations (20)
California
- Visus Therapeutics Investigative Site - Glendale
- Visus Therapeutics Investigative Site - Inglewood
- Visus Therapeutics Investigative Site - Irvine
- Visus Therapeutics Investigative Site - Mission Hills
- Visus Therapeutics Investigative Site - Newport Beach
- Visus Therapeutics Investigative Site - Pasadena
- Visus Therapeutics Investigative Site - Santa Barbara
Florida
- Visus Therapeutics Investigative Site - Crystal River
- Visus Therapeutics Investigative Site - Delray Beach
- Visus Therapeutics Investigative Site - Fort Lauderdale
- Visus Therapeutics Investigative Site - Jacksonville
- Visus Therapeutics Investigative Site - Largo
- Visus Therapeutics Investigative Site - Mt. Dora
Arizona
- Visus Therapeutics Investigative Site - Chandler
- Visus Therapeutics Investigative Site - Phoenix
- Visus Therapeutics Investigative Site - Sun City
Colorado
- Visus Therapeutics Investigative Site - Littleton
Connecticut
- Visus Therapeutics Investigative Site - Danbury
Illinois
- Visus Therapeutics Investigative Site - Lake Villa
Indiana
- Visus Therapeutics Investigative Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 629 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 3 |
What the finished NCT05135286 record still lists
NCT05135286 is an interventional study that assigns participants to a tested intervention. The registered 629 participants enrollment target is mid-sized for trials with a published cap, above the 254-participant average among 38 other Presbyopia trials with a reported enrollment target (148% higher).
The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 3 interventions - of which Vehicle is the first listed.
NCT05135286 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05135286 about?
NCT05135286 is a clinical study titled "Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia". Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
What is the current status of trial NCT05135286?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 629 participants. The study started on 2022-03-15. Estimated completion is 2025-03-13.
What conditions does trial NCT05135286 study?
This clinical trial studies the following conditions: Presbyopia.
What interventions are being tested in trial NCT05135286?
The interventions under investigation include: Vehicle (DRUG), BRIMOCHOL™ PF (DRUG), Carbachol PF (DRUG).
Who is sponsoring clinical trial NCT05135286?
This trial is sponsored by Visus Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05135286 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05135286's enrollment target sits among peer trials
629 2nd of 38 the highest of 38 other Presbyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase III Presbyopia Correction Using the VIS Opti-K™ System
RECRUITING · Phase 3
-
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
COMPLETED · Phase 3
-
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
COMPLETED · Phase 3
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI